Outpost Bio is decoding the hidden interactions that drive human biology. The company combines high-throughput assays of human-derived microbial communities with machine learning to build frontier models that reveal causal pathways - not just correlations. Headquartered in Boston and London, the company enables any partner developing molecules that go into or onto humans to predict microbe-mediated metabolism, toxicity, and response - making human microbiology computable for the first time.
Outpost Bio: Venture Capital Funding History
Outpost Bio
- Life Sciences
- London, United Kingdom
- £2.6m
- outpost.bio
- Update Information
More venture news
- 5 Nov 2026

Alethio TherapeuticsAlethio Therapeutics secures a £67m Series A round led by Sofinnova Partners and RA Capital to develop targeted blood cancer therapies
Series ALife Sciences - 5 Nov 2026

Potential SciencesPotential Sciences launches from stealth with an eight figure investment led by UK Sovereign AI Fund and Twin Path Ventures for its frontier lab for chemistry
EquityLife Sciences - 26 Oct 2026

adsilicoadsilico unlocks a £10m Series A round led by PXN Ventures for virtual testing of implantable medical devices
Series ALife Sciences
